潮宏基(002345.SZ)一季度預盈1億-1.1億元 同比扭虧為盈
格隆匯3月29日丨潮宏基(002345.SZ)公佈,預計2021年第一季度歸屬於上市公司股東的淨利潤1億元-1.1億元,上年同期虧損2275.77萬元。
去年第一季度受新冠疫情影響,公司業務受到較大的衝擊,營業收入大幅下降,而相關運營成本支出相對剛性,導致2020年第一季度利潤同比下降並首次出現虧損。公司在疫情發生之後及時採取應對措施,加快數字化轉型,優化供應鏈,加大產品研發,提升門店運營業績,同時加大加盟業務拓展力度,以及通過多層次直播方式,為線上線下渠道引流增效,經營業績較快得到恢復,並實現增長。2021年第一季度公司經營情況良好,保持良好的增長態勢,經營業績同比預計將實現較大幅度的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.